Oncotalks | Powered by Novartis

ESMO 2020: Dr. Peter Fasching: Pooled analysis of PRO of QOL in M2, M3 and M7

Dr. Peter Fasching speaking on "Pooled analysis of PRO of QOL in M2, M3 and M7"

ESMO

00:03:30

ESMO 2020: Dr. Peter Fasching: Ribociclib vs Palbociclib MAIC analysis

Dr. Peter Fasching speaking on "Ribociclib vs Palbociclib MAIC analysis"

ESMO

00:04:11

ESMO 2020: Dr. Michelino De Laurentiis: Ribociclib dose reduction on OS in M3 and M7

Dr. Michelino De Laurentiis is speaking on "Ribociclib dose reduction on OS in M3 and M7."

ESMO

00:03:49

ESMO 2020: Dr. Sara Hurvitz: Ribociclib and resistance to prior ET in the M3 and M7

Dr. Sara Hurvitz is speaking on "Ribociclib and resistance to prior ET in the M3 and M7".

ESMO

00:02:49

ESMO 2019 Marina Garassino, MD, PhD; Next immunotherapy strategies for lung cancer

Marina Garassino, MD, PhD from Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy is commenting on a session she chared: Special symposium: Next immunotherapy strategies for lung cancer

ESMO , Lithuania , Albania

00:02:46

ESMO 2019 Paolo Ascierto, MD, PhD; Precision medicine in melanoma therapy

Paolo Ascierto, MD, PhD from Istituto Nazionale Tumori IRCCS Fondazione, Napoli, Italy is commenting on a session he chaired: Special Symposium: Precision medicine in melanoma therapy

ESMO , Lithuania , Albania

00:03:21

ESMO 2019 Jorge Reis-Filho, MD, PhD; Where will future technologies take us in metastatic breast cancer?

Jorge Reis-Filho, MD, PhD from the Memorial Sloan Kettering Cancer Center, New York, USA is commenting on the session he chaired: Special Symposium: Where will future technologies take us in metastatic breast cancer?

ESMO , Lithuania , Albania

00:04:52

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Conleth Murphy, MD, PhD from the Bon Secours Cork Cancer Centre, Cork, Ireland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Kisqali Channel , Hungary , Lithuania , Albania

00:03:01

ESMO 2019- Highlights on lungcancer presented at ESMO 2019

Yen Shen Lu, MD, PhD shared his personal highlights on lung cancer presented at ESMO 2019 in Barcelona

ESMO , Lithuania , Albania

00:02:42

ESMO 2019 Rachel Giles, PhD; Diagnosis, management, and burden of renal cell carcinomas

Rachel Giles, PhD from Medicom Medical Publishers, Utrecht, The Netherlands is commenting on the abstract: 915PD - Diagnosis, management, and burden of renal cell carcinomas: Results from a global patient survey in 43 countries

ESMO , Hungary , Lithuania , Albania

00:05:16

ESMO 2019 Elżbieta Senkus-Konefka, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Elżbieta Senkus-Konefka, MD, PhD from the Medical University of Gdansk, Poland is commenting on the abstract LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)Video in Polish

ESMO , Lithuania , Albania

00:03:59

ESMO 2019 Ivan Bilić, MD, PhD'; Overall survival (OS) results of the Phase III MONALEESA-3 trial

Ivan Bilić, MD, PhD from the University Hospital Centre Zagreb, Croatia is commenting on the abstract: LBA7_PR - Overall survival (OS) results of the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2−) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB)

ESMO , Lithuania , Albania

00:06:08

ESMO

ESMO 2020: Dr. Peter Fasching: Pooled analysis of PRO of QOL in M2, M3 and M7

ESMO 2020: Dr. Peter Fasching: Ribociclib vs Palbociclib MAIC analysis

ESMO 2020: Dr. Michelino De Laurentiis: Ribociclib dose reduction on OS in M3 and M7

ESMO 2020: Dr. Sara Hurvitz: Ribociclib and resistance to prior ET in the M3 and M7

ESMO 2019 Marina Garassino, MD, PhD; Next immunotherapy strategies for lung cancer​

ESMO 2019 Paolo Ascierto, MD, PhD; Precision medicine in melanoma therapy​

ESMO 2019 Jorge Reis-Filho, MD, PhD; Where will future technologies take us in metastatic breast cancer?​

ESMO 2019 Conleth Murphy, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019- Highlights on lungcancer presented at ESMO 2019

ESMO 2019 Rachel Giles, PhD; Diagnosis, management, and burden of renal cell carcinomas

ESMO 2019 Elżbieta Senkus-Konefka, MD, PhD; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Ivan Bilić, MD, PhD'; Overall survival (OS) results of the Phase III MONALEESA-3 trial

ESMO 2019 Marina Garassino, MD, PhD; Next immunotherapy strategies for lung cancer

ESMO 2019 Paolo Ascierto, MD, PhD; Precision medicine in melanoma therapy

ESMO 2019 Jorge Reis-Filho, MD, PhD; Where will future technologies take us in metastatic breast cancer?